BOSTON (

TheStreet

) -- The October biotech calendar is chock-full of potentially stock moving events, including a dozen drugs facing U.S. approval decisions.

Phase III or pivotal studies that could report results in October:

  • Bristol-Myers (BMY) - Get Report Squibb's melanoma drug ipilimumab.
  • Corcept Therapeutics' (CORT) - Get Report Corlux in Cushing's syndrome.
  • Seattle Genetics' (SGEN) - Get Report brentuximab vedotin in anaplastic large cell lymphoma.
  • Cyclacel Pharmaceuticals' (CYCC) - Get Report seliciclib in non-small cell lung cancer.

Oct. 1

FDA drug approval decision:

Hospira'

(HSP)

Dyloject for acute moderate-to-severe pain in adults.

FDA drug approval decisions:

Johnson & Johnson

(JNJ) - Get Report

Nucynta for pain indications.

Oct. 4

FDA drug approval decision:

Human Genome Sciences'

( HGSI) Zalbin for hepatitis C.

Oct. 8-12

European Society for Medical Oncology annual meeting. Data presentations to include

Johnson & Johnson

(JNJ) - Get Report

(abiraterone),

Oxigene

(OXGN)

(Zybrestat), Seattle Genetics (SGN-75),

Allos Therapeutics

( ALTH) (Folotyn) and

Arqule

(ARQL) - Get Report

(ARQ197).

The Obesity Society annual meeting. Stocks of interest include

Arena Pharmaceuticals

(ARNA) - Get Report

,

Vivus

(VVUS) - Get Report

and

Orexigen Therapeutics

(OREX)

.

Oct. 11

FDA drug approval decision:

Alexza Pharmaceuticals'

(ALXA)

AZ-004 for agitation in patients with schizophrenia or bipolar disorder.

FDA drug approval decision:

Jazz Pharmaceuticals'

(JAZZ) - Get Report

JZP-6 for fibromyalgia.

Oct. 12

FDA drug approval decision:

Alkermes

(ALKS) - Get Report

Vivitrol for opioid addiction.

Oct 13-16

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Data presentations to include

Sanofi-Aventis

(SNY) - Get Report

(Teriflunomide),

Biogen Idec

(BIIB) - Get Report

and

Elan

(ELN)

(Tysabri) and

Genzyme

( GENZ) (Campath).

Oct. 18

FDA advisory panel to discuss the use of erythropoeisis-stimulating agents in the treatment of patients with chronic kidney failure.

Amgen

(AMGN) - Get Report

(Aranesp, Epogen), Johnson & Johnson (Procrit) and

Affymax

(AFFY)

(Hematide).

Oct. 19

BioMarin Pharmaceuticals

(BMRN) - Get Report

analyst/investor day.

Oct. 20

Genzyme third-quarter earnings announcement.

Oct. 22

FDA drug approval decision:

Arena Pharmaceuticals'

(ARNA) - Get Report

lorcaserin for obesity

FDA drug approval decision:

Amylin Pharmaceuticals

( AMLN), Alkermes and

Eli Lilly's

(LLY) - Get Report

Bydureon for diabetes.

Oct. 28

FDA drug approval decision:

Vivus'

(VVUS) - Get Report

Qnexa for obesity.

Oct. 29

FDA drug approval decision:

Avanir Pharmaceuticals'

(AVNR)

Zenvia for pseudobulbar affect.

FDA drug approval decision:

Forest Labs

(FRX)

ceftaroline for Community Acquired Pneumonia.Oct. 30

FDA drug approval decision:

Biodel's

(BIOD)

Linjeta for diabetes.

Exact Sciences

(EXAS) - Get Report

presentation of external validation study of its genetic stool test for colon cancer.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.